Product Description
CNTX-6016 is a novel, potent and highly selective investigational cannabinoid 2 (CB2) agonist currently in Phase 1 clinical trials.
Mechanisms of Action: CB2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Centrexion
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Chronic Pain|Nociceptive Pain|Healthy Volunteers|Pain Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CNTX-6016o-HV/PDN-102 | P1 |
Completed |
Healthy Volunteers|Pain Unspecified |
2023-08-30 |
28% |
| CNTX-6016o-HV-101 | P1 |
Completed |
Chronic Pain|Nociceptive Pain |
2019-08-21 |
45% |